Compounding risks to patients: selective disclosure is not an option.
McGoey
Linsey
L
Institute for Science, Innovation, and Society, Saïd Business School, University of Oxford, Park End Street, Oxford. linsey.mcgoey@sbs.ox.ac.uk
D022126:Access to Information / Q000941:ethics; D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects; D002648:Child; D002986:Clinical Trials as Topic / Q000941:ethics*; D003132:Commerce / Q000941:ethics; D016265:Conflict of Interest; D004345:Drug Industry / Q000941:ethics*; D026689:Ethical Analysis; D006801:Humans; D007258:Informed Consent / Q000941:ethics*; D028681:Moral Obligations; D017374:Paroxetine / Q000009:adverse effects; D012108:Research Personnel; D035842:Research Subjects; D016896:Treatment Outcome; D014342:Truth Disclosure / Q000941:ethics*; D006113:United Kingdom; D014481:United States
D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine